Company / Operating Income
Seres Therapeutics, Inc. Operating Income History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$195.1M
FY2025
5-year range
-$195.1M / -$64.5M
FY2021-FY2025
Trend
-202.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed -203% YoY in FY2025, a notable deviation from the 9-year average annual change of -73%.
Based on SEC 10-K filings.
-$195M in FY2025.
Declined from -$88M to -$195M over the past 3 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 202.5% year-over-year.
- Peak operating income was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$195.1M | -202.5% |
| FY2023 | -$64.5M | +26.8% |
| FY2022 | -$88.1M | -22.6% |
| FY2021 | -$71.9M | +28.3% |
| FY2020 | -$100.3M | -9.7% |
| FY2019 | -$91.4M | +1.6% |
| FY2018 | -$92.8M | -69.2% |
| FY2017 | -$54.9M | -263.7% |
| FY2016 | -$15.1M | -149.2% |
| FY2015 | -$6.1M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026